Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
24
Frequently Asked Questions
What is Market Cap of Neuphoria Therapeutics Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Neuphoria Therapeutics Inc. market cap is $24.42M.
What is the 52-week high for Neuphoria Therapeutics Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Neuphoria Therapeutics Inc. 52 week high is $13.34 as of September 09, 2025.
What is the 52-week low for Neuphoria Therapeutics Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Neuphoria Therapeutics Inc. 52 week low is $2.12 as of September 09, 2025.
What is Neuphoria Therapeutics Inc. stock price today?
Neuphoria Therapeutics Inc. stock price today is $15.10.
What was Neuphoria Therapeutics Inc. stock price yesterday?
Neuphoria Therapeutics Inc. stock price yesterday was $12.99.
What is the PE ratio of Neuphoria Therapeutics Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Neuphoria Therapeutics Inc.’s P/E ratio is -206.52.
What is the Price-to-Book ratio of Neuphoria Therapeutics Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Neuphoria Therapeutics Inc. P/B ratio is 0.9264.
What is the 50-day moving average of Neuphoria Therapeutics Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Neuphoria Therapeutics Inc. 50-day moving average is $8.34.
How many employess does Neuphoria Therapeutics Inc. has?